Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.30 |
| ▸ | PRKACA | P17612 | 2/20 | 0.30 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.30 |
| ▸ | CDK8 | P49336 | 2/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309365 | 0.77 | ADORA2A (0.47) | ADORA2AADORA2B | |
| SCHEMBL3482963 | 0.69 | ADORA2A (0.42) | ADORA2AADORA2B | |
| SCHEMBL12303980 | 0.65 | ADORA2A (0.42) | ADORA2AADORA2BPIM3PIM2DAPK3 | |
| SCHEMBL13283350 | 0.65 | PIM3 (0.57) | ADORA2AADORA2BPIM3PIM2DAPK3 | |
| SCHEMBL3482791 | 0.63 | ADORA2A (0.48) | ADORA2AADORA2B | |
| SCHEMBL3483061 | 0.63 | ADORA2A (0.48) | ADORA2AADORA2B | |
| SCHEMBL3483035 | 0.63 | ADORA2A (0.48) | ADORA2AADORA2B | |
| SCHEMBL1099775 | 0.63 | ADORA2A (0.48) | ADORA2AADORA2B | |
| SCHEMBL12303983 | 0.63 | ADORA2A (0.54) | ADORA2AADORA2BPIM3PIM2 | |
| SCHEMBL12806939 | 0.60 | PIM3 (0.51) | ADORA2AADORA2BPIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-1898244-B | Triazole derivatives as vasopressin antagonists | PFIZER | 2011-06-22 | — | — | CN | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1569954-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052921-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | CTSF, CTSB, CTSK | ADORA2A 4529/4885ADORA2B 3145/4885PIM3 2620/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | ADORA2A 405/4885ADORA2B 284/4885PIM3 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.